Carolyn Bertozzi

Stanford Professor Carolyn Bertozzi discusses the development of drugs called LYTACs that can degrade disease-causing proteins. The conversation covers the engineering of these drugs, their benefits, and future optimization. They explore the concept of proteolysis targeting chimeras as an alternative to traditional drugs and the potential therapeutic applications of lytac technology. The episode also discusses advancements in drug design, optimizing lie tech for therapeutics, and the potential of targeted protein degradation for improving patient outcomes.

Carolyn Bertozzi, Nobel Prize-winning chemist, discusses the unstructured process of science and how breakthroughs can come from unexpected places. She also highlights the challenges faced by newcomers in the field and emphasizes the importance of personal chemistry in running a successful lab. The podcast explores the distinction between day science and night science, the role of creativity in research, and the value of collaborations. It also discusses the frustrations and breakthroughs in tuberculosis study and the concept of the long game in science.